Accutane blamed for teenage suicide, in $70 million lawsuit

21 April 2002

Following on the story above, Hoffman-La Roche's anti-acne drug Accutanehas found itself at the center of another lawsuit. The family of 15-year-old Charles Bishop, who died January 5 when he crashed a stolen plane into a Tampa, Florida, high-rise building, is suing the drugmaker for $70 million, alleging that the medicine initiated his actions. The family also demands that the drug be removed from the market.

Depression has been listed on the drug's label as a possible side effect since 1985 and, in 1998, the US Food and Drug Administration said that suicide was also possible. A Roche spokeswoman, however, said the company was unaware of the lawsuit and maintained that the drug is safe. "We continue, as do the experts, to believe there is no link," she said. According to the FDA, 147 people taking Accutane either committed suicide or were hospitalized for suicide attempts between 1982 and 2000.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight